CHI Advisors LLC
- SEC CIK
- 0001791468
- Latest filing
- Nov 13, 2023
Holdings in Q3 2023
Holdings as of Sep 30, 2023, filed Nov 13, 2023. Long positions only; changes compare share counts with Q2 2023.
- Positions
- 26
- +1 vs. Q2 2023
- Portfolio value
- $252.1M
- −$77.3M (−23.5%) vs. Q2 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PLRXPliant Therapeutics, Inc. | COM | 3,014,199 | $52.3M | 20.7% | −102,818−3.3% | Reduced | History |
| RPTXRepare Therapeutics Inc. | COM | 2,966,674 | $35.8M | 14.2% | −32,060−1.1% | Reduced | History |
| CGEMCullinan Therapeutics, Inc. | COM | 3,414,189 | $30.9M | 12.3% | 00.0% | Unchanged | History |
| SLRNACELYRIN, Inc. | COM | 2,262,990 | $23.0M | 9.1% | −400,816−15.0% | Reduced | History |
| ORTXOrchard Therapeutics plc | SPON ADS NEW | 12,315,654 | $14.0M | 5.6% | +11,559,916+1,529.6% | Added | History |
| LRMRLarimar Therapeutics, Inc. | COM | 3,414,468 | $13.5M | 5.4% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 407,633 | $13.0M | 5.2% | +5,515+1.4% | Added | History |
| IMAImageneBio, Inc. | COM | 2,180,934 | $9.44M | 3.7% | +58,894+2.8% | Added | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 215,000 | $7.66M | 3.0% | +130,000+152.9% | Added | History |
| CMPXCompass Therapeutics, Inc. | COM | 2,829,712 | $5.57M | 2.2% | 00.0% | Unchanged | History |
| MLYSMineralys Therapeutics, Inc. | COM | 568,379 | $5.41M | 2.1% | +568,379 | New | History |
| INZYInozyme Pharma, Inc. | COM | 1,270,027 | $5.33M | 2.1% | +75,000+6.3% | Added | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 1,299,359 | $5.12M | 2.0% | +531,914+69.3% | Added | History |
| BPMCBlueprint Medicines Corp | COM | 92,888 | $4.66M | 1.9% | +92,888 | New | History |
| Direxion Shs ETF Tr25460G716 | DAILY S&P BIOTEC | 225,000 | $4.63M | 1.8% | −100,000−30.8% | Reduced | – |
| TSVT2seventy bio, Inc. | COMMON STOCK | 1,002,007 | $3.93M | 1.6% | +150,000+17.6% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 60,000 | $3.42M | 1.4% | +60,000 | New | History |
| OVIDOvid Therapeutics Inc. | COM | 864,822 | $3.32M | 1.3% | 00.0% | Unchanged | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 348,842 | $3.07M | 1.2% | +348,842 | New | History |
| OMGAOmega Therapeutics, Inc. | COMMON STOCK | 1,055,882 | $2.27M | 0.9% | 00.0% | Unchanged | History |
| BDTXBlack Diamond Therapeutics, Inc. | COM | 720,000 | $2.07M | 0.8% | −30,000−4.0% | Reduced | History |
| RLYBRallybio Corp | COM | 390,734 | $1.32M | 0.5% | −152,040−28.0% | Reduced | History |
| IRONDisc Medicine, Inc. | COM | 25,000 | $1.17M | 0.5% | −100,139−80.0% | Reduced | History |
| LENZLENZ Therapeutics, Inc. | COM | 230,938 | $572.7K | 0.2% | 00.0% | Unchanged | History |
| Freeline Therapeutics Hldgs35655L206 | SPONSORED ADS | 86,654 | $372.6K | 0.1% | +64,988+300.0% | Added | – |
| DTILPrecision Biosciences Inc | COM | 606,629 | $207.0K | 0.1% | −996,928−62.2% | Reduced | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q2 2023 (3)
Positions held at the end of Q2 2023 that are gone from this filing.